Scarica l'app Stockscreener
26.69
0.37%
-0.10
Pre-mercato:
27.99
1.30
+4.87%
Precedente Chiudi:
$26.79
Aprire:
$27
Volume 24 ore:
98,507
Relative Volume:
0.64
Capitalizzazione di mercato:
$734.00M
Reddito:
-
Utile/perdita netta:
$-69.47M
Rapporto P/E:
-4.7684
EPS:
-5.5973
Flusso di cassa netto:
$-73.92M
1 W Prestazione:
+4.75%
1M Prestazione:
-2.09%
6M Prestazione:
+13.33%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$26.52
$27.12
Intervallo di 1 settimana:
$24.60
$27.46
Portata 52W:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Nome
Lenz Therapeutics Inc
Settore
Industria
Telefono
858-925-7000
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Confronta LENZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
26.69 | 734.00M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-04-10 | Iniziato | Citigroup | Buy |
| 2024-03-27 | Iniziato | Piper Sandler | Overweight |
| 2023-02-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-14 | Iniziato | BTIG Research | Buy |
| 2022-03-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Iniziato | Morgan Stanley | Overweight |
| 2021-07-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Target Price from Brokerages - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading 8% HigherWhat's Next? - MarketBeat
Leerink Partnrs Has Negative Outlook of LENZ FY2025 Earnings - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5.1%What's Next? - MarketBeat
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Leerink Partnrs Has Pessimistic View of LENZ FY2025 Earnings - Defense World
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - Citeline News & Insights
Myopia Pipeline 2024: Detailed Clinical Trials - openPR
LENZ Therapeutics (LENZ) Expected to Announce Earnings on Wednesday - Defense World
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight - EIN News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Sees Significant Increase in Short Interest - Defense World
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) Short Interest Down 5.0% in December - Defense World
LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World
Morgan Stanley Cuts U.S. Bancorp (NYSE:USB) Price Target to $59.00 - Defense World
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9% - MarketBeat
Barclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5%Time to Sell? - MarketBeat
Trio-Tech International (NYSE:TRT) Coverage Initiated by Analysts at StockNews.com - Defense World
Harbor Capital Advisors Inc. Buys Shares of 43,989 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Jane Street Group LLC Acquires Shares of 12,027 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9%Here's What Happened - MarketBeat
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Lenz Therapeutics New Becomes Oversold (LENZ) - Nasdaq
Financial Survey: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
Head to Head Contrast: Allied Resources (ALOD) versus Its Peers - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
SkyWater Technology, Inc. (NASDAQ:SKYT) Shares Purchased by Barclays PLC - Defense World
NI Holdings, Inc. (NASDAQ:NODK) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Raises Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
Neumora plummets on depression drug data - BioPharma Dive
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Raises Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp - MarketBeat
Jane Street Group LLC Cuts Stock Holdings in Jpmorgan Betabuilders U.S. Treasury Bond 20+ Year ETF (NYSEARCA:BBLB) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3%Should You Buy? - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1% – What’s Next? - Defense World
Wellington Management Group LLP Invests $585,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1%Time to Sell? - MarketBeat
BNP Paribas Financial Markets Has $63,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Presbyopia Therapeutics Market Size was highest in the US among the 7MM, was ~USD 8,039 million, and is expected to increase by 2034 | DelveInsight - Barchart
Presbyopia Therapeutics Market Size was highest in the US among - openPR
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 5.8%Here's What Happened - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40 - Defense World
Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.82%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):